At present, combining CDK4/6 inhibitors (such as palbociclib, ribociclib, or abemaciclib) with endocrine therapy represents the leading treatment strategy for individuals with hormone receptor positive and HER2 negative advanced breast cancer [15,16]. Here, NR4A1 is linked to breast cancer.